Anavex Life Sciences Corp. has appointed Terrie Kellmeyer, Ph.D., as its permanent President and Chief Executive Officer and as a member of the Board of Directors, effective November 1, 2026. Dr. Kellmeyer, who had been serving as Interim CEO since May 2026, will maintain an annual base salary of $500,000 with an anticipated 30% bonus. The appointment follows her leadership during a period of clinical program focus and increased engagement with the FDA.
Three directors, including Board Chair Dr. Jiong Ma, resigned from the Board of Anavex Life Sciences Corp. effective October 28, 2026. The resignations of Dr. Ma, Mr. Gautam Patel, and Dr. Adrian Senderowicz were due to disagreements regarding the company's strategic direction and business plan execution. The company subsequently reconstituted its Audit, Compensation, and Nominating committees on November 1, 2026.
Anavex Life Sciences announced the completion of clinical conduct for two pharmacology studies (ADME and DDI) for blarcamesine (ANAVEX 2-73) in healthy volunteers. The company also reported FDA clearance of its IND application for Fragile X syndrome and an upcoming November meeting with the FDA regarding its Phase 3 Rett syndrome study.
Anavex Life Sciences received FDA clearance for its Investigational New Drug (IND) application for blarcamesine (ANAVEX 2-73) to treat Fragile X syndrome. This allows the company to proceed with a Phase 2a clinical study in approximately 60 adult males, marking a key milestone as the company now has open INDs in Alzheimer’s, Rett syndrome, and Fragile X.
Anavex Life Sciences Corp. held its 2026 Annual Meeting of Stockholders on September 24, 2026, where a contested election resulted in the appointment of new directors. The election triggered a 'change in control' provision under the company's incentive plans because incumbent directors no longer constitute a majority of the board, resulting in the immediate vesting of all outstanding unvested equity awards.